Robert McRae
Net worth: 1 735 $ as of 30/03/2024
Profile
Robert McRae worked as Vice President-Operations at Viracta Subsidiary, Inc. from 2018 to 2020.
He also held the position of Vice President-Operations & Strategic Alliances at Viracta Therapeutics, Inc. Additionally, he served as Chief Operating Officer at Palisade Bio, Inc. in 2023.
Mr. McRae obtained his undergraduate degree from Wright State University (Ohio).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PALISADE BIO, INC.
0.03% | 14/03/2024 | 4,348 ( 0.03% ) | 1 735 $ | 30/03/2024 |
Former positions of Robert McRae
| Companies | Position | End |
|---|---|---|
| PALISADE BIO, INC. | Chief Operating Officer | 30/04/2023 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Chief Operating Officer | - |
Training of Robert McRae
| Wright State University (Ohio) | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| PALISADE BIO, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
- Stock Market
- Insiders
- Robert McRae
